Pierre-Alain Ruffieux, PhD
Chief Executive Officer (CEO) and Member of the Executive Committee (from November 2020 until September 2023)
Pierre-Alain Ruffieux holds a doctorate in Biotechnology and a master’s degree in Chemical Engineering and Biotechnology from the Swiss Federal Institute of Technology (EPFL), Lausanne (CH).
Former Activities and Functions
- Head of Global Pharma Technical Operations & Member Pharma Executive Team, F. Hoffmann-La Roche (2017–2020)
- Head of Quality and Compliance, Global Pharma Technical Operations, F. Hoffmann-La Roche (2015–2017)
- Head of Quality, Pharmaceutical Division & Member Pharmaceutical Executive Committee, Novartis Pharmaceuticals (2012–2015)
- Head of Global Pharma Technical Operations & Biologics Quality Assurance, Novartis Pharmaceuticals (2010–2012)
- Global Head of Quality for Biopharmaceutical, Novartis Pharmaceuticals (2009–2010)
- Various positions in technical development and manufacturing at Novartis Pharmaceuticals & Sandoz, Novartis Group (2003–2009)
- Various positions in technical development and manufacturing at Serono (now Merck Serono) (1998–2003)
Caroline Barth
Chief Human Resources Officer (CHRO) and Member of the Executive Committee
(from May 2020 until April 2023)
Caroline Barth holds a degree in European Business Studies from the University of Sunderland (UK) and an MBA from The Open University, Brussels (BE).
Former Activities and Functions
- Global Head of Human Resources, Pharma, Novartis Pharma AG (2016–2020)
- Global Head Pharma Strategy, Novartis Pharma AG (2019)
- Global Head of Human Resources, Pharma Manufacturing and Quality, Novartis Pharma AG (2014–2016)
- Global Head of Human Resources, Central & Eastern Europe, Novartis Pharma AG (2013–2014)
- VP, Human Resources Canada Pharma & Corporate HR Leader, Novartis Pharma AG (2010–2013)
- Head of Talent Management, Organizational Development & Staffing, Europe, Novartis Pharma AG (2008–2010)
- Head of Human Resources Global IT, Novartis Pharma AG (2006–2008)
- Human Resources Integration Leader, Novartis Pharma AG (2004–2006)
- HR Communications Leader, EMEA & APAC, Cisco Systems (2001–2003)
- HR Generalist, Emerging Markets, Cisco Systems (1997–2001)
Albert M. Baehny
Chief Executive Officer (CEO) ad interim (since October 2023), Chairman of the Board of Directors of Lonza Group Ltd (2018 - 2024), Independent member of the Board of Directors of Lonza Group Ltd (2017 - 2024).
On 1 October 2023, Albert M. Baehny took on the responsibilities as CEO ad interim.
Albert M. Baehny holds a degree in biology from the University of Fribourg (CH).
Public Company Boards:
- Member of the Board of Directors of Investis Group Holding SA (since 2016)
- Chairman of the Board of Directors of Geberit AG (since 2011)
Former Activities and Functions
- CEO ad interim of Lonza Group Ltd (2019–2020)
- CEO of Geberit Group (2005–2014)
- Head of Group Division Marketing and Sales Europe for Geberit Group (2003–2004)
- Senior Vice-President at Wacker Chemie AG (2001–2002)
- Various Marketing, Sales, Strategic Planning and Global Management Positions with:
- Vantico (2000–2001)
- Ciba-Geigy / Ciba Specialty Chemicals (1994–2000)
- Dow Chemicals Europe (1981–1993)
- Serono-Hypolab (1979–1981)
Dorothée Deuring
Independent member of the Board of Directors of Lonza Group Ltd (April 2020 until May 2022)
Non-Executive Director and Corporate Finance Adviser, who brings more than 25 years of experience in the fields of manufacturing, biotech, pharmaceuticals and finance. Ms Deuring currently serves on the board of several companies including Axpo, Immofinanz and Elementis. Her Board memberships span the energy, chemical and biopharmaceutical sectors. She received her Master of Science in Chemistry from Université Louis Pasteur, Strasbourg in 1994. She later received her Master in Business Administration from INSEAD, Fontainebleau (France) in 1996.
Current activities and functions
Public Company Board Mandates:
- Member of the Board of Directors, Member of the Audit Committee of Axpo Holding AG (since 2017)
- Member of the Board of Directors, Member of the Audit and Remuneration Committees of Elementis PLC (since 2017)
Activity:
- Independent Corporate Finance Adviser (since 2014)
Former activities and functions
- Supervisory Board Member, Immofinanz AG (2021–2022)
- Supervisory Board Member, Member of the Audit Committee of Bilfinger SE (2016–2021)
- Member of the Board of Directors of PIQUR Therapeutics AG (2019–2021)
- Member of the Board of Directors of Selecta AG (2020)
- Supervisory Board Member (Beirat) of Röchling Group SE & Co. KG (2016–2019)
- Head of Corporate Advisory Group Europe, Managing Director Wealth Management Division of UBS AG (2011–2014)
- Managing Director Investment Banking, Head Healthcare and Chemicals M&A of Bankhaus Sal. Oppenheim Jr & Cie (2007–2009)
- Vice Director, Corporate Finance, Mergers & Acquisitions; Vice Director, Diagnostics Division, Business Development for F. Hoffman-La Roche AG (2003–2007)
- Founder, Owner Manager and Board Member of CoCap AG (1998–2003)
- Consultant of McKinsey & Company (1997–1998)
- Managing Director of K. Deuring & Co (1993–1997)